trial

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

NCTId NCT04325737
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 13 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2020-08-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
13 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2020-03-31
Primary completion
2020-08-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Ulotaront

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Sites

8 total
Omuta-shi, JapanOsaka-Fu, JapanUeda-shi, JapanKunigami-gun, JapanKanzaki, JapanKaratsu-shi, JapanTosu, JapanFukuoka, Japan

Facts & assertions

4 sourced
Enrollment
13
Phase
PHASE1
Primary Completion Date
2020-08-07
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication